Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H40O5 |
Molecular Weight | 408.5714 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(O)=O
InChI
InChIKey=BHQCQFFYRZLCQQ-UTLSPDKDSA-N
InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19+,20+,22+,23+,24-/m1/s1
Ursocholic acid (UCA) is the 7 beta epimer of the naturally occurring primary bile acid, cholic acid. Cholic acid (CA) administration does not reduce biliary cholesterol saturation unless its 7 alpha dehydroxylation to deoxycholic acid (DCA) is prevented by concomitant antibiotic treatment. It was shown, that UCA caused diarrhoea and hypercholesterolemia, had only a modest effect on biliary cholesterol saturation and thus UCA was not able to replace ursodeoxycholic and chenodeoxycholic acid for medical treatment of gallstones. In addition, as discovered, during ursocholic acid therapy the synthesis of primary bile acids continued whereas the formation of secondary bile acids was greatly increase.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of ursocholic acid on bile lipid secretion and composition. | 1986 Apr |
|
Effect of chronic ursocholic acid administration on bile lipid composition and bile acid pool size in gallstone patients. | 1990 Jul |
|
Metabolism of ursocholic acid in humans: conversion of ursocholic acid to deoxycholic acid. | 1992 Apr |
|
Ursocholic acid, a hydrophilic bile acid, fails to improve liver function parameters in primary biliary cirrhosis: comparison with ursodeoxycholic acid. | 1997 Jun |
|
A paucity of unusual trihydroxy bile acids in the urine of patients with severe liver diseases. | 1999 May |
|
FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. | 2005 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9177526
were fed ursocholic acid 900 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15591588
Caco-2 cells were treated with 10 μM hydrophobic bile acids DCA, CDCA, and CA, which activate FXR, and 10 μM ursocholic acid (UCA), which almost do not activate FXR, for 40 h. Neither UCA nor ursochenodeoxycholic acid (UDCA) significantly reduced luciferase activity in P2 with intact α-fetoprotein transcription factor (FTF) binding site.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID301018756
Created by
admin on Fri Dec 15 15:17:49 GMT 2023 , Edited by admin on Fri Dec 15 15:17:49 GMT 2023
|
PRIMARY | |||
|
81240
Created by
admin on Fri Dec 15 15:17:49 GMT 2023 , Edited by admin on Fri Dec 15 15:17:49 GMT 2023
|
PRIMARY | |||
|
MLP1T05RBX
Created by
admin on Fri Dec 15 15:17:49 GMT 2023 , Edited by admin on Fri Dec 15 15:17:49 GMT 2023
|
PRIMARY | |||
|
122340
Created by
admin on Fri Dec 15 15:17:49 GMT 2023 , Edited by admin on Fri Dec 15 15:17:49 GMT 2023
|
PRIMARY | |||
|
SUB11390MIG
Created by
admin on Fri Dec 15 15:17:49 GMT 2023 , Edited by admin on Fri Dec 15 15:17:49 GMT 2023
|
PRIMARY | |||
|
2955-27-3
Created by
admin on Fri Dec 15 15:17:49 GMT 2023 , Edited by admin on Fri Dec 15 15:17:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY